Cytek Biosciences, Inc. (CTKB)
After hours:
- GlobeNewswire
Cytek Biosciences Reports First Quarter 2024 Financial Results
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023First quarter revenue from the prod
- Zacks
Cytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should Know
In the most recent trading session, Cytek Biosciences, Inc. (CTKB) closed at $6.01, indicating a -0.33% shift from the previous trading day.
- GlobeNewswire
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
Company to Conduct Educational Workshops and Tutorials at CYTO and AAI’s IMMUNOLOGY2024FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by actively participating in key industry gatherings worldwide. The company's Full Spectrum Profiling™ (FSP™) technology, designed for streamlining workflows, expediting discoveries, and enhancing efficiency, will b
